Pharma sector should focus on quality. affordable manufacturing: Mandaviya

The industry is progressing at a rapid rate, and to maintain our stature as the 'Pharmacy of the World', he added

Mansukh L Mandaviya
Union Health Minister Mansukh L Mandaviya (PTI Photo)
Press Trust of India New Delhi
2 min read Last Updated : May 27 2023 | 3:06 PM IST

The domestic pharmaceutical industry should focus on quality and affordable manufacturing in order to compete globally, Union minister Mansukh Mandaviya said on Saturday.

Speaking at a round-table conference with CEOs of leading pharmaceutical companies, Mandaviya also asked the industry to have enhanced focus on research and innovation in the sector.

"The industry is progressing at a rapid rate, and to maintain our stature as the 'Pharmacy of the World', we need to focus on quality and affordable manufacturing with an increased focus on research and innovation," Mandaviya said in the meeting as per a government statement.

The chemicals and fertilisers minister urged the stakeholders to capitalise on the current opportunities, stating that substantial investment in terms of production linked incentive schemes as well as upcoming drug parks are bearing fruitful results.

To catalyse growth, the industry must maintain a degree of competitiveness to consolidate presence in the world, Mandaviya said.

Reiterating the government's commitment and resolve, the Union health minister stated that the government is industry-friendly and welcomes opportunities for collaboration.

The government and industry, both integral to the nation's progress, must work cohesively to achieve holistic growth, he noted.

Affirming government support, Mandaviya invited the stakeholders to put forth their suggestions addressing the aspects of pricing, regulatory, policy and strategy, with the respective action points in a detailed presentation.

He noted that due consideration will be given to facilitate further policy support and growth.

The roundtable saw participation from over 60 companies represented by senior leadership.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Pharma sectorMansukh Lal Mandaviya

First Published: May 27 2023 | 3:06 PM IST

Next Story